Abstract

Compounds of formula 1,

wherein:

R¹ is hydrogen, hydroxy, CF₃, NO₂, CN, halogen, C₁-C₈-alkyl, or C₁-C₈-alkoxy;

 R^2 , R^3 , and R^4 independently of one another are hydrogen, C_1 - C_8 -alkyl, hydroxy, NO_2 , CN, C_1 - C_8 -alkyloxy, CF_3 , or halogen;

 R^5 and R^6 independently of one another are hydrogen or a group consisting of C_1 - C_8 -alkyl, C_2 - C_8 -alkenyl, C_3 - C_8 -cycloalkyl, C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkylene, C_5 - C_8 -cycloalkenyl, C_5 - C_8 -cycloalkenyl- C_1 - C_6 -alkylene, C_6 - C_{10} -aryl, and C_6 - C_{10} -aryl- C_1 - C_6 -alkylene, each optionally substituted by a group consisting of C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, halogen, C_1 - C_6 -alkyloxy, -NH₂, -NH(C_1 - C_4 -alkyl), -N(C_1 - C_4 -alkyl)₂, hydroxy, =O, -COOH, -CO-OC₁- C_4 -alkyl, -CONH₂, -CONH(C_1 - C_4 -alkyl), -CON(C_1 - C_4 -alkyl)₂, and CF₃, or

 R^5 and R^6 together with the nitrogen atom are a saturated or unsaturated 5-, 6-, 7-, or 8-membered heterocyclic group optionally containing one or two further heteroatoms consisting of sulfur, oxygen, and nitrogen, and optionally mono-, di-, or trisubstituted by a group consisting of C_1 - C_4 -alkyl, hydroxy, =0, -COOH, -CO- OC_1 - C_4 -alkyl, -CONH₂, -CONH(C_1 - C_4 -alkyl), -CON(C_1 - C_4 -alkyl)₂, halogen, and benzyl;

X is oxygen, -NH-, -N(CHO)-, -N(CO- C_1 - C_6 -alkyl), -N(C_1 - C_6 -alkyl), or -N(C_3 - C_6 -cycloalkyl- C_1 - C_4 -alkylene); and

A is a group consisting of C₁-C₆-alkylene, C₂-C₆-alkenylene, and C₃-C₆-alkynylene, each optionally substituted by a group consisting of halogen, =O, and hydroxy,

or an optical isomer, enantiomer, tautomer, free base, or pharmacologically acceptable acid addition salt thereof; methods of making such compounds; pharmaceutical compositions thereof, and their use in treating or preventing certain diseases.